The agreement between HER2T and HER3P measurements is also understandable, since HER2 preferentially phosphorylates HER3 [37] and HER3 receptor is functionally involved in the biology of HER2-positive breast tumors and now represents a new molecular target of therapy [38]. The gene discussed is ERBB2; the disease is breast neoplasm.